Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill

Recruiting

Conditions: Primary Immunodeficiency Diseases (PID)

Interventions: Other: No Intervention

First Posted Date: 2023-11-29

Last Posted Date: 2024-12-20

Lead Sponsor: Takeda

Target Recruit Count: 36

Registration Number: NCT06150534

Locations: 🇺🇸
Research Triangle Park, Raleigh, North Carolina, United States

A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Brigatinib

First Posted Date: 2023-11-15

Last Posted Date: 2024-02-26

Lead Sponsor: Takeda

Target Recruit Count: 12

Registration Number: NCT06132867

Locations: 🇺🇸
Celerion, Inc., Tempe, Arizona, United States

A Study of TAK-279 in Healthy Chinese Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-279
Drug: Placebo

First Posted Date: 2023-11-01

Last Posted Date: 2024-08-07

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT06111547

Locations: 🇨🇳
Huashan Hospital Fudan University, Shanghai, China

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Phase 3

Active, not recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: TAK-279
Drug: Placebo
Drug: Apremilast

First Posted Date: 2023-10-31

Last Posted Date: 2024-10-16

Lead Sponsor: Takeda

Target Recruit Count: 1108

Registration Number: NCT06108544

Locations: 🇺🇸
Advanced Medical Research, PC, Atlanta, Georgia, United States
🇨🇦
Skinsense Medical Research - 411 2nd Ave N - Probity - PPDS, Saskatoon, Saskatchewan, Canada
🇵🇱
ETG Siedlce - PPDS, Siedlce, Mazowieckie, Poland

and more 214 locations

A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone

Withdrawn

Conditions: Hodgkin Lymphoma

Interventions: Other: No Intervention

First Posted Date: 2023-10-27

Last Posted Date: 2024-03-06

Lead Sponsor: Takeda

Registration Number: NCT06104878

Locations: 🇧🇷
Oncoclinicas Rio de Janeiro S.A, Rio de Janeiro, Brazil
🇧🇷
AC Camargo Cancer Center / Fundação Antonio Prudente Liberdade, Sao Paulo, Brazil
🇧🇷
Beneficência Portuguesa de São Paulo - Real Benemerita Associação Portuguesa de Beneficência, Sao Paulo, Brazil

and more 3 locations

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Phase 3

Not yet recruiting

Conditions: Crohn's Disease
Ulcerative Colitis

Interventions: Drug: Vedolizumab SC
Drug: Vedolizumab IV

First Posted Date: 2023-10-25

Last Posted Date: 2024-12-20

Lead Sponsor: Takeda

Target Recruit Count: 70

Registration Number: NCT06100289

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Phase 4

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Vedolizumab
Drug: Tofacitinib

First Posted Date: 2023-10-23

Last Posted Date: 2024-12-27

Lead Sponsor: Takeda

Target Recruit Count: 65

Registration Number: NCT06095128

Locations: 🇺🇸
Digestive Health Specialsits, Dothan, Alabama, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Hoag Hospital Newport Beach, Newport Beach, California, United States

and more 45 locations

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Phase 3

Active, not recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: TAK-279
Drug: Placebo
Drug: Apremilast

First Posted Date: 2023-10-18

Last Posted Date: 2024-10-16

Lead Sponsor: Takeda

Target Recruit Count: 693

Registration Number: NCT06088043

Locations: 🇺🇸
Saguaro Dermatology Associates, LLC - Probity - PPDS, Phoenix, Arizona, United States
🇺🇸
First OC Dermatology - Fountain Valley, Fountain Valley, California, United States
🇺🇸
Center for Dermatology Clinical Research, Fremont, California, United States

and more 129 locations

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Phase 3

Recruiting

Conditions: Primary Immunodeficiency Diseases (PID)

Interventions: Biological: TAK-881
Device: SC Investigational Needle Sets

First Posted Date: 2023-10-11

Last Posted Date: 2024-12-20

Lead Sponsor: Takeda

Target Recruit Count: 39

Registration Number: NCT06076642

Locations: 🇺🇸
Sneeze, Wheeze, & Itch Associates, LLC, Normal, Illinois, United States
🇺🇸
Central Georgia Infectious Disease Consultants, Macon, Georgia, United States

A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India

Phase 3

Recruiting

Conditions: Healthy Volunteers

Interventions: Biological: TDV
Biological: Placebo

First Posted Date: 2023-09-29

Last Posted Date: 2024-12-09

Lead Sponsor: Takeda

Target Recruit Count: 480

Registration Number: NCT06060067

Locations: 🇮🇳
BGS Global Institute of Medical Sciences (BGS-GIMS) #67, BGS Health & Education City, Uttarahalli Main Road, Kengeri, Bangalore, Karnataka, India
🇮🇳
IPGME&R and SSKM Hospital, 244 AJC Bose Road, Kolkata, India
🇮🇳
Chettinad Academy of Research and Education, Chettinad Health City, SH,49A, Dist. Kelambakkam, Pudupakkam, Tamil Nadu, India

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy